3CGT
| |
7KP9
| asymmetric hTNF-alpha | 分子名称: | 1-{[2-(difluoromethoxy)phenyl]methyl}-2-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1H-benzimidazole, Tumor necrosis factor | 著者 | Arakaki, T.L, Abendroth, J, Fairman, J.W, Foley, A, Ceska, T. | 登録日 | 2020-11-10 | 公開日 | 2021-01-13 | 最終更新日 | 2024-04-03 | 実験手法 | X-RAY DIFFRACTION (2.15 Å) | 主引用文献 | Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF. Nat Commun, 12, 2021
|
|
7KP8
| asymmetric mTNF-alpha hTNFR1 complex | 分子名称: | 1-{[2-(difluoromethoxy)phenyl]methyl}-2-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1H-benzimidazole, Tumor necrosis factor, Tumor necrosis factor receptor superfamily member 1A | 著者 | Arakaki, T.L, Fox III, D, Edwards, T.E, Foley, A, Ceska, T. | 登録日 | 2020-11-10 | 公開日 | 2021-01-13 | 最終更新日 | 2024-04-03 | 実験手法 | X-RAY DIFFRACTION (3.15 Å) | 主引用文献 | Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF. Nat Commun, 12, 2021
|
|
8DN1
| Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V at pH 7.2 | 分子名称: | (2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form, GLYCEROL, ... | 著者 | Bingham, C.R, Borhan, B, Geiger, J.H. | 登録日 | 2022-07-10 | 公開日 | 2023-02-01 | 最終更新日 | 2023-10-25 | 実験手法 | X-RAY DIFFRACTION (1.32 Å) | 主引用文献 | Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins. Analyst, 148, 2023
|
|
8D6H
| Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V after UV irradiation | 分子名称: | (2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form, ACETATE ION, ... | 著者 | Bingham, C.R, Geiger, J.H, Borhan, B. | 登録日 | 2022-06-06 | 公開日 | 2023-02-01 | 最終更新日 | 2023-10-25 | 実験手法 | X-RAY DIFFRACTION (1.6 Å) | 主引用文献 | Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins. Analyst, 148, 2023
|
|
8D6N
| Q108K:K40L:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V | 分子名称: | (2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form, ACETATE ION, ... | 著者 | Bingham, C.R, Geiger, J.H, Borhan, B. | 登録日 | 2022-06-06 | 公開日 | 2023-02-01 | 最終更新日 | 2023-10-25 | 実験手法 | X-RAY DIFFRACTION (1.42 Å) | 主引用文献 | Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins. Analyst, 148, 2023
|
|
8DB2
| Q108K:K40L:T51C:T53A:R58L:Q38F mutant of hCRBPII bound to synthetic fluorophore CM1V | 分子名称: | (2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form, Retinol-binding protein 2 | 著者 | Bingham, C.R, Geiger, J.H, Borhan, B, Staples, R. | 登録日 | 2022-06-14 | 公開日 | 2023-02-01 | 最終更新日 | 2023-10-25 | 実験手法 | X-RAY DIFFRACTION (1.5 Å) | 主引用文献 | Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins. Analyst, 148, 2023
|
|
8D6L
| Q108K:K40L:T51C:T53A:R58L:Q38F:Q4F mutant of hCRBPII bound to synthetic fluorophore CM1V | 分子名称: | (2E)-3-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]prop-2-enal, bound form, GLYCEROL, ... | 著者 | Bingham, C.R, Geiger, J.H, Borhan, B. | 登録日 | 2022-06-06 | 公開日 | 2023-02-15 | 最終更新日 | 2023-10-25 | 実験手法 | X-RAY DIFFRACTION (1.69 Å) | 主引用文献 | Light controlled reversible Michael addition of cysteine: a new tool for dynamic site-specific labeling of proteins. Analyst, 148, 2023
|
|
1RV1
| CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR | 分子名称: | CIS-[4,5-BIS-(4-BROMOPHENYL)-2-(2-ETHOXY-4-METHOXYPHENYL)-4,5-DIHYDROIMIDAZOL-1-YL]-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]METHANONE, Ubiquitin-protein ligase E3 Mdm2 | 著者 | Lukacs, C, Kammlott, U, Graves, B. | 登録日 | 2003-12-12 | 公開日 | 2004-01-20 | 最終更新日 | 2023-08-23 | 実験手法 | X-RAY DIFFRACTION (2.3 Å) | 主引用文献 | In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 2004
|
|
3NBP
| HIV-1 reverse transcriptase with aminopyrimidine inhibitor 2 | 分子名称: | 4-(4-{[4-(4-cyano-2,6-dimethylphenoxy)pyrimidin-2-yl]amino}piperidin-1-yl)benzenesulfonamide, MANGANESE (II) ION, Reverse transcriptase/ribonuclease H, ... | 著者 | Harris, S.F, Villasenor, A.G. | 登録日 | 2010-06-03 | 公開日 | 2010-08-18 | 最終更新日 | 2024-02-21 | 実験手法 | X-RAY DIFFRACTION (2.95 Å) | 主引用文献 | Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. Bioorg.Med.Chem.Lett., 20, 2010
|
|
6E51
| |
6E50
| |
6E5E
| |
6E5Q
| |
5CGT
| |
6E6L
| |
6E7M
| |
6E5R
| |
6E5S
| |
5DPQ
| Crystal Structure of E72A mutant of domain swapped dimer Human Cellular Retinol Binding Protein | 分子名称: | ACETATE ION, Retinol-binding protein 2 | 著者 | Assar, Z, Nossoni, Z, Wang, W, Geiger, J.H, Borhan, B. | 登録日 | 2015-09-14 | 公開日 | 2016-09-14 | 最終更新日 | 2024-03-06 | 実験手法 | X-RAY DIFFRACTION (1.775 Å) | 主引用文献 | Domain-Swapped Dimers of Intracellular Lipid-Binding Proteins: Evidence for Ordered Folding Intermediates. Structure, 24, 2016
|
|
7CGT
| |
6MR0
| |
6MOX
| |
6MVP
| HCV NS5B 1b N316 bound to Compound 18 | 分子名称: | (4-{[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl](methylsulfonyl)amino}phenyl)boronic acid, Genome polyprotein | 著者 | Williams, S.P, Kahler, K, Price, D.J, Peat, A.J. | 登録日 | 2018-10-26 | 公開日 | 2019-09-04 | 最終更新日 | 2024-03-13 | 実験手法 | X-RAY DIFFRACTION (2 Å) | 主引用文献 | Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor. J.Med.Chem., 62, 2019
|
|
6MVO
| HCV NS5B 1A Y316 bound to Compound 49 | 分子名称: | 6-[(7-chloro-1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)(methylsulfonyl)amino]-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide, RNA-directed RNA polymerase, SULFATE ION | 著者 | Williams, S.P, Kahler, K, Price, D.J, Peat, A.J. | 登録日 | 2018-10-26 | 公開日 | 2019-09-04 | 最終更新日 | 2024-03-13 | 実験手法 | X-RAY DIFFRACTION (1.95 Å) | 主引用文献 | Design of N-Benzoxaborole Benzofuran GSK8175-Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor. J.Med.Chem., 62, 2019
|
|